We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 24.00 | 0.20% | 11,808.00 | 11,792.00 | 11,796.00 | 11,876.00 | 11,728.00 | 11,728.00 | 1,485,402 | 16:35:15 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 54.07B | 7.04B | 4.5370 | 25.99 | 182.72B |
From Mar 2020 to Mar 2025
By Olga Cotaga
LONDON--AstraZeneca PLC (AZN.LN) said Tuesday it expects to report progression-free survival data for the lung cancer randomized MYSTIC trial in mid-2017, and final overall survival data from the trial in 2018 at the latest.
While the focus remains on exploring the benefit of durvalumab and tremelimumab as a combination therapy, the pharmaceutical company will focus the MYSTIC trial on including overall survival and progression-free survival data in durvalumab monotherapy, it said.
Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga
(END) Dow Jones Newswires
January 17, 2017 02:40 ET (07:40 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
